Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

270 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia.
Woyach JA, Blachly JS, Rogers KA, Bhat SA, Jianfar M, Lozanski G, Weiss DM, Andersen BL, Gulrajani M, Frigault MM, Hamdy A, Izumi R, Munugalavadla V, Quah C, Wang MH, Byrd JC. Woyach JA, et al. Among authors: bhat sa. Cancer Discov. 2020 Mar;10(3):394-405. doi: 10.1158/2159-8290.CD-19-1130. Epub 2020 Jan 8. Cancer Discov. 2020. PMID: 31915195 Free PMC article. Clinical Trial.
Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies.
Rogers KA, Mousa L, Zhao Q, Bhat SA, Byrd JC, El Boghdadly Z, Guerrero T, Levine LB, Lucas F, Shindiapina P, Sigmund AM, Sullivan M, Wiczer TE, Woyach JA, Awan FT. Rogers KA, et al. Among authors: bhat sa. Leukemia. 2019 Oct;33(10):2527-2530. doi: 10.1038/s41375-019-0481-1. Epub 2019 May 13. Leukemia. 2019. PMID: 31086260 Free PMC article. No abstract available.
Hypertension and incident cardiovascular events following ibrutinib initiation.
Dickerson T, Wiczer T, Waller A, Philippon J, Porter K, Haddad D, Guha A, Rogers KA, Bhat S, Byrd JC, Woyach JA, Awan F, Addison D. Dickerson T, et al. Blood. 2019 Nov 28;134(22):1919-1928. doi: 10.1182/blood.2019000840. Blood. 2019. PMID: 31582362 Free PMC article. Clinical Trial.
LC-FACSeq is a method for detecting rare clones in leukemia.
Hu EY, Blachly JS, Saygin C, Ozer HG, Workman SE, Lozanski A, Doong TJ, Chiang CL, Bhat S, Rogers KA, Woyach JA, Coombes KR, Jones D, Muthusamy N, Lozanski G, Byrd JC. Hu EY, et al. JCI Insight. 2020 Jun 18;5(12):e134973. doi: 10.1172/jci.insight.134973. JCI Insight. 2020. PMID: 32554930 Free PMC article.
Second cancer incidence in CLL patients receiving BTK inhibitors.
Bond DA, Huang Y, Fisher JL, Ruppert AS, Owen DH, Bertino EM, Rogers KA, Bhat SA, Grever MR, Jaglowski SM, Maddocks KJ, Byrd JC, Woyach JA. Bond DA, et al. Among authors: bhat sa. Leukemia. 2020 Dec;34(12):3197-3205. doi: 10.1038/s41375-020-0987-6. Epub 2020 Jul 23. Leukemia. 2020. PMID: 32704159 Free PMC article.
Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia.
Rogers KA, Huang Y, Ruppert AS, Abruzzo LV, Andersen BL, Awan FT, Bhat SA, Dean A, Lucas M, Banks C, Grantier C, Heerema NA, Lozanski G, Maddocks KJ, Valentine TR, Weiss DM, Jones JA, Woyach JA, Byrd JC. Rogers KA, et al. Among authors: bhat sa. J Clin Oncol. 2020 Nov 1;38(31):3626-3637. doi: 10.1200/JCO.20.00491. Epub 2020 Aug 14. J Clin Oncol. 2020. PMID: 32795224 Free PMC article. Clinical Trial.
Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome.
Kittai AS, Bond DA, William B, Saad A, Penza S, Efebera Y, Larkin K, Wall SA, Choe HK, Bhatnagar B, Vasu S, Brammer J, Shindiapina P, Long M, Mims A, O'Donnell L, Bhat SA, Rogers KA, Woyach JA, Byrd JC, Jaglowski SM. Kittai AS, et al. Among authors: bhat sa. Blood Adv. 2020 Oct 13;4(19):4648-4652. doi: 10.1182/bloodadvances.2020002783. Blood Adv. 2020. PMID: 33002129 Free PMC article. No abstract available.
270 results